Jade Biosciences (JBIO) Total Non-Current Liabilities (2021 - 2025)

Jade Biosciences (JBIO) has 5 years of Total Non-Current Liabilities data on file, last reported at $2.4 million in Q1 2025.

• For the quarter ending Q1 2025, Total Non-Current Liabilities fell 84.75% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2025 stood at $2.4 million (down 84.75% YoY), and the FY2024 full-year result was $12.0 million, down 32.95% from the prior year.
• Total Non-Current Liabilities for Q1 2025 stood at $2.4 million, down from $12.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $17.9 million in Q4 2023 and bottomed at $2.4 million in Q1 2025.
• The 5-year median for Total Non-Current Liabilities is $10.8 million (2023), against an average of $10.4 million.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 197.96%; it then slumped 84.75% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.9 million in 2021, then soared by 189.46% to $8.5 million in 2022, then surged by 110.82% to $17.9 million in 2023, then tumbled by 32.95% to $12.0 million in 2024, then slumped by 79.85% to $2.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $2.4 million (Q1 2025), $12.0 million (Q4 2024), and $10.4 million (Q3 2024), per Business Quant data.

Peer Comparison